[Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction].
The clinical effects were compared between a thrombolytic agent (urokinase) and a thromboxane synthetase inhibitor (sodium ozagrel) in patients with acute lacunar infarction. All patients had some degree of neurological deficits, which corresponded to the lesions on computerized tomography or magnetic resonance imaging. Urokinase of 420,000 units was given over two days in 11 patients, 160 mg/day of sodium ozagrel was administered for two weeks in 23 patients. The study was followed up to one month after the onset. Urokinase treatment improved motor paresis in 45.5-62.5% of the patients, sodium ozagrel in 68.4-86.7%. Using the combined score of motor paresis and conscious disorder, urokinase group revealed 44.4-45.5% improvement, but sodium ozagrel group 81.0-89.5% (p < 0.05). The rates of suppressive effect in progressing stroke and complete recovery were higher in sodium ozagrel group. Sodium ozagrel was clinically more efficient than urokinase in patients with lacunar infarction.
Sakamoto
T
T
Department of Traumatology and Critical Care Medicine, National Defense Medical College, Tokorozawa, Japan.
Harimoto
K
K
Inoue
S
S
Konishi
A
A
D000208:Acute Disease; D002544:Cerebral Infarction / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008689:Methacrylates / Q000008:administration & dosage / Q000627:therapeutic use*; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000627:therapeutic use*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D008689:Methacrylates; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D013930:Thromboxane-A Synthase; C034364:ozagrel